Literature DB >> 20710057

Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine.

Nicolás Merchante1, Inés Pérez-Camacho, José A Mira, Antonio Rivero, Juan Macías, Angela Camacho, Jesús Gómez-Mateos, Milagros García-Lázaro, Julián Torre-Cisneros, Juan A Pineda.   

Abstract

BACKGROUND: Unexpected cases of severe liver disease in HIV-infected patients have been reported and an association with didanosine (ddI) has been suggested. Transient elastography (TE) might detect patients harbouring such a condition. Our objective was to search for the presence of abnormal liver stiffness (LS) in a cohort of HIV-infected patients without HBV or HCV coinfection and to assess the related factors.
METHODS: A cross-sectional prospective study was conducted. LS was assessed by TE in 258 HIV-infected patients without HBV or HCV coinfection and with no evidence of acute hepatotoxicity or other origins of liver disease. LS values > or =7.2 kPa were considered abnormal. Multivariate analyses were performed to identify factors associated with abnormal LS.
RESULTS: Abnormal LS was observed in 29 (11.2%) patients. A total of 18 (16.4%) patients previously treated with ddI and 11 (7.4%) of those who never received ddI had LS values > or =7.2 kPa (P=0.02). The prevalence of abnormal LS was higher in patients previously treated with abacavir than in those who had never received abacavir (15 [21.7%] versus 14 [7.4%]; P=0.001). After multivariate analyses, age (adjusted odds ratio [AOR] 1.05, 95% confidence interval [CI] 1.002-1.1; P=0.004) alcohol intake >50 g/day (AOR 7.2, 95% CI 2.6-19.7; P<0.0001), CD4(+) T-cell count <200 cells/ml (AOR 3.4, 95% CI 1.06-11.007; P=0.03), time on ddI treatment (AOR 1.31, 95% CI 1.12-1.52; P=0.001) and previous abacavir exposure (AOR 3.01, 95% CI 1.18-7.67; P=0.02) were independently associated with abnormal LS.
CONCLUSIONS: The prevalence of abnormal LS in HIV-infected patients without HBV or HCV coinfection is substantial. Long-term exposure to ddI is a major cause of liver damage in these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20710057     DOI: 10.3851/IMP1612

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  20 in total

1.  HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis.

Authors:  Jennifer C Price; Eric C Seaberg; Sheila Badri; Mallory D Witt; Kristin D'Acunto; Chloe L Thio
Journal:  J Infect Dis       Date:  2012-01-30       Impact factor: 5.226

2.  Human immunodeficiency virus infection and the liver.

Authors:  Megan Crane; David Iser; Sharon R Lewin
Journal:  World J Hepatol       Date:  2012-03-27

3.  A higher correlation of HCV core antigen with CD4+ T cell counts compared with HCV RNA in HCV/HIV-1 coinfected patients.

Authors:  Tao Shen; Xiangmei Chen; Weidong Zhang; Yuanlin Xi; Guanghua Cao; Yuhong Zhi; Shuiwang Wang; Chunhui Xu; Lai Wei; Fengmin Lu; Hui Zhuang
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

Review 4.  Molecular mechanisms of liver fibrosis in HIV/HCV coinfection.

Authors:  Claudio M Mastroianni; Miriam Lichtner; Claudia Mascia; Paola Zuccalà; Vincenzo Vullo
Journal:  Int J Mol Sci       Date:  2014-05-26       Impact factor: 5.923

5.  Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection.

Authors:  Lucia Brescini; Elena Orsetti; Rosaria Gesuita; Francesca Piraccini; Elisa Marchionni; Silvia Staffolani; Pamela Castelli; Davide Drenaggi; Francesco Barchiesi
Journal:  Hepat Mon       Date:  2014-08-05       Impact factor: 0.660

6.  Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.

Authors:  Helen Kovari; Caroline A Sabin; Bruno Ledergerber; Lene Ryom; Peter Reiss; Matthew Law; Christian Pradier; Francois Dabis; Antonella d'Arminio Monforte; Colette Smith; Stephane de Wit; Ole Kirk; Jens D Lundgren; Rainer Weber
Journal:  Open Forum Infect Dis       Date:  2016-01-21       Impact factor: 3.835

Review 7.  Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?

Authors:  Athanasios-Dimitrios Bakasis; Theodoros Androutsakos
Journal:  Cells       Date:  2021-05-15       Impact factor: 6.600

8.  Abnormal liver stiffness assessed using transient elastography (Fibroscan®) in HIV-infected patients without HBV/HCV coinfection receiving combined antiretroviral treatment.

Authors:  Sang Hoon Han; Seung Up Kim; Chang Oh Kim; Su Jin Jeong; Jun Yong Park; Jun Yong Choi; Do Young Kim; Sang Hoon Ahn; Young Goo Song; Kwang-Hyub Han; June Myung Kim
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

9.  Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV.

Authors:  Antonio Rivero-Juárez; Angela Camacho; Nicolás Merchante; Inés Pérez-Camacho; Juan Macias; Carmen Ortiz-Garcia; Celia Cifuentes; Julián Torre-Cisneros; José Peña; Juan A Pineda; Antonio Rivero
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

10.  Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients.

Authors:  Evrim Anadol; Kristina Lust; Christoph Boesecke; Carolynne Schwarze-Zander; Raphael Mohr; Jan-Christian Wasmuth; Jürgen Kurt Rockstroh; Jonel Trebicka
Journal:  PLoS One       Date:  2018-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.